Staphylococcus aureus with reduced susceptibility to vancomycin

S. E. Cosgrove; K. C. Carroll; T. M. Perl

doi:10.1086/422458

Staphylococcus aureus with reduced susceptibility to vancomycin

S. E. Cosgrove, K. C. Carroll, T. M. Perl

Research output: Contribution to journal › Review article › peer-review

122 Scopus citations

Abstract

Infections with Staphylococcus aureus with reduced susceptibility to vancomycin continue to be reported, including 2 cases caused by S. aureus isolates with full resistance to vancomycin. This review first outlines the definitions of vancomycin-intermediate S. aureus (VISA) and vancomycin-resistant S. aureus (VRSA) and risk factors for infection. Next, we describe the mechanisms of resistance and methods of laboratory detection of the organisms. Finally, we address infection control and management issues associated with isolation of VISA and VRSA.

Original language	English (US)
Pages (from-to)	539-545
Number of pages	7
Journal	Clinical Infectious Diseases
Volume	39
Issue number	4
DOIs	https://doi.org/10.1086/422458
State	Published - Aug 15 2004

ASJC Scopus subject areas

Microbiology (medical)
Infectious Diseases

Access to Document

10.1086/422458

Cite this

@article{ee62a7c045a8416f84eecfb1c3575f6c,

title = "Staphylococcus aureus with reduced susceptibility to vancomycin",

abstract = "Infections with Staphylococcus aureus with reduced susceptibility to vancomycin continue to be reported, including 2 cases caused by S. aureus isolates with full resistance to vancomycin. This review first outlines the definitions of vancomycin-intermediate S. aureus (VISA) and vancomycin-resistant S. aureus (VRSA) and risk factors for infection. Next, we describe the mechanisms of resistance and methods of laboratory detection of the organisms. Finally, we address infection control and management issues associated with isolation of VISA and VRSA.",

author = "Cosgrove, {S. E.} and Carroll, {K. C.} and Perl, {T. M.}",

note = "Funding Information: Financial support. This work was supported in part by the Centers for Disease Control and Prevention (grant UR8/CCU315092 to S.E.C. and T.M.P.). Funding Information: Conflict of interest. T.M.P. has been on advisory panels for Cubist, Glaxo SmithKline, and Reptidyne and has served as a speaker for Aventis, Glaxo SmithKline, and Wyeth. K.C.C. has received research funding from Becton Dickinson Diagnostics. S.E.C.: No conflict.",

year = "2004",

month = aug,

day = "15",

doi = "10.1086/422458",

language = "English (US)",

volume = "39",

pages = "539--545",

journal = "Clinical Infectious Diseases",

issn = "1058-4838",

publisher = "Oxford University Press",

number = "4",

}

TY - JOUR

T1 - Staphylococcus aureus with reduced susceptibility to vancomycin

AU - Cosgrove, S. E.

AU - Carroll, K. C.

AU - Perl, T. M.

N1 - Funding Information: Financial support. This work was supported in part by the Centers for Disease Control and Prevention (grant UR8/CCU315092 to S.E.C. and T.M.P.). Funding Information: Conflict of interest. T.M.P. has been on advisory panels for Cubist, Glaxo SmithKline, and Reptidyne and has served as a speaker for Aventis, Glaxo SmithKline, and Wyeth. K.C.C. has received research funding from Becton Dickinson Diagnostics. S.E.C.: No conflict.

PY - 2004/8/15

Y1 - 2004/8/15

N2 - Infections with Staphylococcus aureus with reduced susceptibility to vancomycin continue to be reported, including 2 cases caused by S. aureus isolates with full resistance to vancomycin. This review first outlines the definitions of vancomycin-intermediate S. aureus (VISA) and vancomycin-resistant S. aureus (VRSA) and risk factors for infection. Next, we describe the mechanisms of resistance and methods of laboratory detection of the organisms. Finally, we address infection control and management issues associated with isolation of VISA and VRSA.

AB - Infections with Staphylococcus aureus with reduced susceptibility to vancomycin continue to be reported, including 2 cases caused by S. aureus isolates with full resistance to vancomycin. This review first outlines the definitions of vancomycin-intermediate S. aureus (VISA) and vancomycin-resistant S. aureus (VRSA) and risk factors for infection. Next, we describe the mechanisms of resistance and methods of laboratory detection of the organisms. Finally, we address infection control and management issues associated with isolation of VISA and VRSA.

UR - http://www.scopus.com/inward/record.url?scp=4344700149&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4344700149&partnerID=8YFLogxK

U2 - 10.1086/422458

DO - 10.1086/422458

M3 - Review article

C2 - 15356818

AN - SCOPUS:4344700149

SN - 1058-4838

VL - 39

SP - 539

EP - 545

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

IS - 4

ER -

Staphylococcus aureus with reduced susceptibility to vancomycin

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this